



Aurobindo Pharma receives MCC South Africa approvals for 23 registrations

09th September 2010

Aurobindo Pharma Ltd is pleased to announce that Medicines Control Council (MCC) South Africa has granted 23 registrations to manufacture and market of the following products in South Africa

The products approved are as follows:

Product Names	Strength	Dosage Form	Generic Name
Bavir	300 mg	Tablets	Abacavir Sulfate
Deladex; Soniren; Segiref	200, 250, 400 mg	DR Capsules	Didanosine
Apafar; Stabinez; Zenvir	600 mg	Tablets	Efavirenz
Colazid	150mg+300mg	Tablets	Lamivudine+ Zidovudine
Bindolam	10 mg/ml	Oral Solution	Lamivudine
Bindopin	200 mg	Tablets	Nevirapine
Auro-Ribavirin; Dorik	200 mg	Tablets	Ribavirin
Cylor; Vireno; Zefin	300 mg	Tablets	Tenofovir Disoproxil Fumarate
Zynovir	100, 250 mg	Capsules	Zidovudine
Emtricitabine/Tenofovir Auro; Tyricten	200+300 mg	Tablets	Emtricitabine+Tenofovir Disoproxil Fumarate
Auro-Meloxicam, Flamaryx	7.5, 15 mg	Tablets	Meloxicam
Nysivir	2, 4 g	Oral solution	Didanosine
Zynovir	50mg/5 ml	Oral Solution	Zidovudine
Bindopin	50mg/5 ml	Oral Suspension	Nevirapine

Aurobindo now has a total of 48 products representing 91 registrations approved by the MCC.

About Aurobindo Pharma:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:

Investor Relations

Aurobindo Pharma Limited

Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad

Phone: 040-66725000 / 66725401

Email: ir@aurobindo.com